Stay updated on Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange Detected- The study's Locations section was updated to add numerous new sites across multiple countries and regions, and many existing locations were removed.SummaryDifference4%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check44 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedAdded a new trial site: Tainan, Taiwan, 704, and removed the Tainan City, Taiwan, 704 listing; a government funding status notice was also deleted.SummaryDifference0.2%

- Check66 days agoChange DetectedNo substantive changes to the core study content were detected; observed differences are limited to layout or metadata changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check95 days agoChange DetectedPage updated to Revision: v3.2.0 from Revision: v3.0.2; indicates a new release version with no other substantive content changes.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.